Gwenn Hansen - Sep 1, 2021 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
Chief Scientific Officer
Signature
/s/ Christine Ring, as Attorney-in-Fact for Gwenn Hansen
Stock symbol
NRIX
Transactions as of
Sep 1, 2021
Transactions value $
-$10,032
Form type
4
Date filed
9/2/2021, 04:22 PM
Previous filing
Aug 3, 2021
Next filing
Sep 8, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NRIX Common Stock Options Exercise $2.9K +400 +2.82% $7.26 14.6K Sep 1, 2021 Direct F1, F2
transaction NRIX Common Stock Sale -$12.9K -400 -2.74% $32.34 14.2K Sep 1, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Employee Stock Option (right to buy) Options Exercise $0 -400 -0.56% $0.00 71.1K Sep 1, 2021 Common Stock 400 $7.26 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2 Includes 393 shares of Common Stock acquired by the Reporting Person on August 13, 2021 pursuant to the Issuer's employee stock purchase plan.
F3 The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.